Real-World Study of Lanreotide Autogel for the Treatment of Patients With Acromegaly in China
Status: Completed
Location: See all (12) locations...
Study Type: Observational
SUMMARY
This study aims to assess the one-year effectiveness and safety of LAN among patients with acromegaly in China in routine clinical practice. In addition, the study is designed to understand the real-world treatment patterns and outcomes of LAN among Chinese patients with acromegaly.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Participants who are able to comply with the protocol
• Participants with serum IGF-1 level above the ULN for age and sex, and serum fasting GH level above 2.5 μg/L
• Participants with acromegaly who are naïve to LAN treatment and about to initiate LAN
Locations
Other Locations
China
Peking Union Medical College Hospital (PUMCH)
Beijing
Peking University Third Hospital (PUH3)
Beijing
Xiangya Hospital Central South University (XYHCSU)
Changsha
West China Hospital，Sichuan University (WCH)
Chengdu
The First Affiliated Hospital,Sun Yat-sen University (FAHSYSU)
Guangzhou
The Second Affiliated Hospital Zhejiang University School of Medicine (SAHZU)
Hangzhou
Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School (NJDTH)
Nanjing
The First Hospital of China Medical University (CMU1H)
Shenyang
The Second Hospital of Hebei Medical University (HB2H)
Shijiazhuang
Affiliated Hospital of Wenzhou Medical University (FAHWMU)
Wenzhou
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology (TJH HUST)
Wuhan
The First Affiliated Hospital of Zhengzhou University (FAHZZU)
Zhengzhou
Time Frame
Start Date: 2022-06-30
Completion Date: 2024-12-13
Participants
Target number of participants: 129
Related Therapeutic Areas
Sponsors
Leads: Ipsen